Welcome!

News Feed Item

Fifth MiMedx Scientific Study Published In Peer-Reviewed Journal

Study determines allografts with both amnion and chorion contain approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated

MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature. 

The Company's peer-reviewed article, "Cytokines in Single Layer Amnion/Chorion Allografts Compared to Multi-Layer Amnion/Chorion Allografts for Wound Healing," was electronically published in the Journal of Biomedical Materials Research Part B: Applied Biomaterials, on August 30, 2014. The paper was authored by Thomas J. Koob, PhD; Jeremy J. Lim, PhD; Nicole Zabek; and Michelle Massee. The electronic publication of the study in the Journal of Biomedical Materials Research is now available in the Wiley Online Library at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33265/pdf

The Company's previously published analyses have determined that over 50 growth factors, chemokines, cytokines, and regulatory factors are contained in PURION® Processed dehydrated human amnion/chorion membrane (dHACM) tissue allografts, specifically EpiFix®, a bilayer laminated graft containing both amnion and chorion. The scientific study was conducted to determine the relative contribution of each layer to the overall growth factor and cytokine content, as well as biological activity in the allograft. The study compared the results to the growth factor content in five representative commercially available single layer amnion grafts.

Study Highlights include:

  • MiMedx's multilayer amnion/chorion grafts (EpiFix® and AmnioFix®) contain approximately 20 times more growth factors and cytokines than the competitive single layer amnion grafts evaluated in the study.
  • AmbioDry2®, the MiMedx PURION® Processed single layer amnion, contains  four to five times greater amounts of growth factors than the competitive single layer amnion products (DryFlex®, AmnioExCel®, SteriShield™, and SteriShield II™) that were evaluated in the study.
  • EpiFix® contains four to five times the growth factors in AmbioDry2®.
  • All single layer amnion grafts that were tested contained substantially fewer growth factors and cytokines, and therefore, will deliver significantly less growth factors and cytokines than MiMedx's amnion/chorion multilayer grafts with the same surface area.
  • When calculated per surface area of tissue applied to a wound, the evaluated PURION® Processed amnion contained on average only 25% of the growth factor content contained in the PURION® Processed chorion.
  • The chorion layer in the MiMedx multi-layered allografts is four to five times thicker than the amnion layer, and therefore, contributes disproportionately to the growth factor content in amnion/chorion grafts. Chorion contributes on average 82% of the growth factors in EpiFix®.

"Recently, there has been misinformation in the market making the generalization that all amniotic membrane grafts are similar, regardless of whether they are single layer amnion or multi-layer allografts," said Parker H. Petit, Chairman and CEO.  "This study confirms that there is a substantial differentiation between multi-layer allografts with both amnion and chorion versus the single layer amnion allografts tested. This scientific study clearly demonstrates that PURION® Processed allografts with both amnion and chorion have a multiple of approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated in the study."

To examine the role of tissue processing technique in cytokine retention, cytokine contents in representative dehydrated single layer wound care products (DryFlex®, AmnioExCel®, SteriShield™ Single Layer, and SteriShield II™ Dual Layer) were measured. The results demonstrated that cytokine content varied significantly among the allografts tested, and that PURION® Processed single layer amnion grafts, AmbioDry2®, contained significantly more cytokines than the other single layer products that were evaluated in the study. "AmbioDry2® is the single layer wound care product MiMedx processes for its ophthalmic partner, IOP Ophthalmics, Inc. These results suggest that, as compared to other methods of tissue processing, the proprietary PURION® Processing contributes to greater cytokine retention and the delivery of substantially more growth factors, which are known to be critically important in wound repair and tissue regeneration," commented Bill Taylor, President and COO.

The publication suggests that the retention of biologically active growth factors during processing of amniotic tissues is critically important in preserving the bioactivity of the native tissues for wound care. "The abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds," stated Taylor.

The ability to induce fibroblast proliferation was studied, and it was determined that both the amnion and chorion caused dermal fibroblasts to proliferate. However, the chorion per square cm was on average five times more effective at inducing proliferation. "The study determined that the predominant basis for the bioactivity is derived from the chorion. This is a clear indication that the biological activity in EpiFix® that induces fibroblast proliferation is a result of both our proprietary processing technique and the graft's multi-layer configuration with both amnion and chorion," concluded Petit.

DryFlex®and AmnioExCel® are registered trademarks, and SteriShield™ and SteriShield II™ are trademarks of their respective owners. AmbioDry2® is private labeled for, and is a registered trademark of, IOP Ophthalmics, Inc.

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the importance of biologically active growth factors during processing of amniotic tissues in preserving the bioactivity of the native tissues for wound care and the contribution of the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts to these allografts' effectiveness in promoting the healing of refractive wounds.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the retention of biologically active growth factors during processing of amniotic tissues may prove not to be as important in preserving the bioactivity of the native tissues for wound care as the study suggests, that, in a head-to-head study,  the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may be found not to contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013.  By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at 18th Cloud Expo, Sagi Brody, Chief Technology Officer at Webair Internet Development Inc., will focus on real world deployments of DDoS mitigation strategies in every layer of the network. He will give an overview of methods to prevent these attacks and best practices on how to provide protection in complex cloud platforms. He will also outline what we have found in our experience managing and running thousands of Linux and Unix managed service platforms and what specifically c...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
The demand for organizations to expand their infrastructure to multiple IT environments like the cloud, on-premise, mobile, bring your own device (BYOD) and the Internet of Things (IoT) continues to grow. As this hybrid infrastructure increases, the challenge to monitor the security of these systems increases in volume and complexity. In his session at 18th Cloud Expo, Stephen Coty, Chief Security Evangelist at Alert Logic, will show how properly configured and managed security architecture can...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
A critical component of any IoT project is the back-end systems that capture data from remote IoT devices and structure it in a way to answer useful questions. Traditional data warehouse and analytical systems are mature technologies that can be used to handle large data sets, but they are not well suited to many IoT-scale products and the need for real-time insights. At Fuze, we have developed a backend platform as part of our mobility-oriented cloud service that uses Big Data-based approache...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
As the rapid adoption of containers continues, companies are finding that they lack the operational tools to understand the behavior of applications deployed in these containers, and how to identify issues in their application infrastructure. For example, how are multiple containers within an application impacting each other’s performance? If an application’s service is degraded, which container is to blame? In the case of an application outage, what was the root cause of the outage?
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...